Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

You are here:

Author: Shervin Assassi, Roozbeh Sharif, Robert E Lasky, Terry A McNearney, Rosa M Estrada-Y-Martin, Hilda T Draeger, Deepthi K Nair, Marvin J Fritzler, John D Reveille, Frank C Arnett, Maureen D Mayes and The GENISOS Study
Date Published: September-2010
Source: Arthritis Research & Therapy

The objective was to examine the association of baseline demographic and clinical characteristics with sequentially obtained measurements of forced vital capacity (FVC, expressed as a percentage of the predicted value) and to identify predictors of decline rate in FVC over time in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS).

in this section...

SRF Mailing List

donate now

Make an online contribution
to help find a cure for
scleroderma. It’s fast, secure and simple.

quick links

moving forward video

"Moving Forward" is a five minute video sharing the struggles presented by scleroderma.

Ways to Give

There are many ways that you can support the work of the Scleroderma Research Foundation. We are grateful for your commitment to helping the SRF fund research that will result in improved therapies and, ultimately, a cure.

» Click here for details

Make a Donation 1-800-441-CURE (2873)

The Scleroderma Research Foundation is a 501(c)3 nonprofit organization whose mission is to fund and facilitate the most promising medical research aimed at improved therapies and, ultimately, a cure for scleroderma. Information provided by the SRF should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The SRF does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Scleroderma varies substantially from one patient to another, and treatment must be tailored by a physician for each individual case.